Medical Device News

What are the future trends of medical devices? In the rapidly evolving landscape of healthcare, staying informed about the latest advancements in medical technology is essential for professionals and enthusiasts alike. Medical Device News Magazine serves as a vital resource, offering insights into cutting-edge innovations, regulatory developments, and industry trends that impact both patient care and business strategies. This publication aims to bridge the gap between healthcare professionals, investors, and the medical device industry, providing a comprehensive platform of medical device news that can result in discussions on medical device/biotechnology advancements and their implications for the future of medicine.

Read on as we explore the intersection of technology and healthcare, facilitating informed decision-making and fostering collaboration within this dynamic field. Inquire about advertising. Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

Industry Expert Byline

How Prioritizing Employee Mental Wellness Creates a More Positive, Engaged Workforce | By Dawn Griffin, chief human resources & diversity officer at TRIMEDX

Medical Device News Magazine - December 4, 2024

Organizations that prioritize employee mental wellness foster a happier, healthier workforce that is more engaged, resilient, and productive. Acknowledging mental wellness is one of the ways a company can show it values its employees’ overall wellbeing, which helps to attract and retain top talent. A 2023 American Psychology Association (APA) survey found 92% of people said it is very or somewhat important to them to work for an organization that values their emotional and psychological wellbeing. By supporting mental wellness, companies...

Medical Device News Updates

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

November 14, 2024

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

November 14, 2024

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Mergers & Acquisitions & Funding

Poseida Therapeutics Announces Agreement to be Acquired by Roche Holdings, Inc.

November 26, 2024 0

The proposed acquisition will establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused on CAR-T programs covered by the existing strategic collaboration between Poseida and Roche in hematologic malignancies. It will include CAR-T programs for solid tumors and autoimmune diseases, along with Poseida's genetic engineering platform and related preclinical medicines.

Cytomos Secures £5M | To Scale Up Production of Cell-analysis Technology

November 19, 2024 0

New investment will allow Cytomos to drive sales of its first commercial product, Celledonia™, built on its cell-analysis technology platform AuraCyt, which is already generating significant market traction.

Clinical Trials & Updates

Anocca Announces Submission of Clinical Trial Application for Multi-asset Trial VIDAR-1 in Advanced Pancreatic Cancer

November 26, 2024 0

Hugh Salter, Chief Scientific Officer at Anocca, elaborated, "KRAS is an immensely important target in many cancer types, but has to date been challenging to address. KRAS mutations are a hallmark of PDAC, which is among the most difficult to treat cancers, and we believe TCR-T cell therapies and, in particular, our VIDAR-1 assets can be effective in addressing this target and providing a new solution in an indication with high unmet medical need.”

Enterprise Therapeutics Publishes on Medicinal Chemistry of ETD001 | A Novel Inhaled ENaC Blocker for Treatment of Cystic Fibrosis

November 19, 2024 0

The paper describes the medicinal chemistry optimisation of a new series of ENaC blockers, resulting in the invention of ETD001, Enterprise’s lead asset, a potential new inhaled treatment for cystic fibrosis notes Enterprise Therapeutics.

Byline Articles

How Prioritizing Employee Mental Wellness Creates a More Positive, Engaged Workforce | By Dawn Griffin, chief human resources & diversity officer at TRIMEDX

December 4, 2024 0

Organizations that prioritize employee mental wellness foster a happier,...

From Standardized to Specialized: Revolutionizing Lung Cancer Care | By Ofer Sharon, MD, CEO of OncoHost

December 2, 2024 0

The future of lung cancer care lies in placing each patient’s unique biology at the center of every clinical decision. Through collaboration, innovation, and an unwavering commitment to advancing science, we can move closer to a world where every lung cancer patient benefits from a truly personalized treatment plan.

Biotechnology News

Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the “AD-DMT Registry” in...

November 26, 2024 0

Eisai and Biogen Japan will continue to contribute to the advancement of Alzheimer’s disease treatment through ongoing collaboration with academia.

Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial (“INVINCIBLE-3 Study”) in...

November 18, 2024 0

Phase 1/2 data showed a median overall survival (“mOS”) of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone notes Intensity Therapeutics.

FDA Updates

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDEÒ Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

November 4, 2024 0

Christopher M. Owens, President and Chief Executive Officer of R3 Vascular. “Initiation of this trial will begin in Q1 2025 and will be conducted at up to 60 global clinical sites with 264 subjects, and upon favorable conclusion will allow the company to complete and pursue a PMA market application for MAGNITUDE with the FDA.”

Exactech Reports the FDA Clearance of Truliant® Porous 3D Tibial Implant for Knee Replacement Surgery

October 31, 2024 0

The Truliant Porous Tibial Tray leverages additive manufacturing technology to create a porous structure designed to mimic the structure of cancellous bone. This design aims to facilitate both initial and biological fixation, designed to accommodate patients' active lifestyles notes Exactech.

Headlines

Philips and AWS Expand Strategic Collaboration to Advance HealthSuite Cloud Services and Power Generative AI Workflows

Medical Device News Magazine - November 26, 2024

“The collaboration between Philips and AWS gives healthcare providers scalable, secure-by-design cloud-enabled solutions to accelerate healthcare innovation,” said Matt Garman, CEO of AWS. “Combining Philips’ healthcare informatics portfolio with AWS generative AI capabilities gives clinicians access to imaging insights so they can deliver more effective and efficient care to patients anywhere, anytime, with best-in-class security and privacy.”

Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis

Medical Device News Magazine - October 25, 2024

“This latest expansion of coverage by Noridian means that even more patients could be positively impacted by PlaqueIQ, which offers the only non-invasive measurement of lipid-rich necrotic core, a vulnerable, high-risk component of plaque that can lead to heart attack and stroke,”4 said Kelly Huang, CEO of Elucid. “These recent decisions from five of the seven MACs recognize the importance of new technologies like ours that can help quantify and classify coronary artery plaque to help physicians reduce the clinical and economic burden of cardiovascular disease.”

Market Reports

In Vitro Diagnostics Quality Controls Global Markets: Revenue Data for 2021-2023, Estimated Figures for 2024, and Projected CAGRs Through 2029

October 21, 2024

Global Laparoscopic Device Market Poised for Growth Amid Technological Advancements and Increasing Procedural Volume

October 17, 2024

Real-world Evidence Solutions Market | To be Worth $6.37 Billion by 2031

August 19, 2024

Europe $3.53 Bn Sleep Apnea Devices Markets 2024-2032 by Types, Therapeutic Devices, Diagnostic Devices, End User, and Company Analysis

July 24, 2024

Hospitals In the News

The Northwell Health Constellation Gala Raises More Than $3.2M To Support Health Care Innovation In Manhattan

Medical Device News Magazine - November 26, 2024

This year’s event was hosted by actress and comedian Cecily Strong and featured a musical performance by the Orchestra of St. Luke’s. Proceeds will provide greater access to high-quality care by helping to advance services and programs across Manhattan at Lenox Hill Hospital, Manhattan Eye, Ear & Throat Hospital, Lenox Health Greenwich Village – and soon, the Victoria and Lloyd Goldman Health Care Pavilion, a state-of-the-art outpatient care facility that is slated to open on the Upper East Side in 2026.

Executives Making Headlines

Nusano Names Medical Radioisotopes Advisory Board

EXECUTIVES December 4, 2024 0

“As a radioisotope producer, Nusano plays a critical role in the supply chains of drug developers, healthcare providers and researchers,” said Chris Lowe, CEO of Nusano. “Establishing a Medical Radioisotopes Advisory Board reflects our ongoing commitment to proactively enabling the next generation of oncology research. The board’s guidance will ensure Nusano is providing a stable and scalable supply of isotopes for new areas of research and patient care.”

Jason Whiting Appointed CEO of Avation Medical

EXECUTIVES November 4, 2024 0

Jason Whiting has more than 25 years of experience in the MedTech industry, driving innovation and adoption of new technologies in the implantable, capital equipment, and wearable markets.

Non-Profit Updates

Non Profit News

Cold Weather Exposure Linked to Increased Risk of Heart Attacks

JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, said the study reveals a crucial link between cold weather exposure and heart attack risk, highlighting a delayed effect that peaks days after the cold spell.

Ryan Reynolds Announces More to Parkinson’s® Campaign

Ryan Reynolds said, “My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease. Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease.”

New Paper Underscores Inflammation’s Role in Atherosclerosis

Peter Libby, MD, President, of the International Atherosclerosis Society and Chair of the White Paper Expert Panel said, "Atherosclerosis is a primary cause of cardiovascular disease, the leading cause of death worldwide. This paper underscores the persistent need for a more complete understanding of the role of inflammation in atherosclerosis progression among physicians globally, how to identify such inflammation, and how to mitigate the inflammation-associated risk of adverse cardiovascular events. These steps are of the utmost importance for the development of effective treatment strategies that can reduce the morbidity and mortality caused by atherosclerotic cardiovascular disease."

Study: Private Equity Acquisitions in Cardiology on the Rise

“Policymakers and clinicians have raised concern about the growing presence of private equity in other medical specialties. Although cardiology is an attractive target for private equity firms, little is known about the number and types of practices that are being acquired,” said Senior Author Rishi K. Wadhera, MD, MPP, MPhil, a cardiologist at Beth Israel Deaconess Medical Center and associate professor at Harvard Medical School in Boston. “Private equity acquisitions in other specialties have been shown to decrease quality and increase costs, so it is critical to understand the impact on cardiology.”